» Authors » Robert E Geertsma

Robert E Geertsma

Explore the profile of Robert E Geertsma including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 563
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoogervorst L, Ren Y, Melvin T, Stratton-Powell A, Lubbeke A, Geertsma R, et al.
Acta Orthop . 2024 Nov; 95:667-676. PMID: 39584822
Background And Purpose:  Safety notices for medical devices such as total knee arthroplasty (TKA) implants may indicate problems in their design or performance that require corrective action to prevent patient...
2.
Jennen D, van Herwijnen M, Jetten M, Vandebriel R, Keizers P, Geertsma R, et al.
Int J Mol Sci . 2022 Nov; 23(21). PMID: 36361846
Usage of injectable dermal fillers applied for aesthetic purposes has extensively increased over the years. As such, the number of related adverse reactions has increased, including patients showing severe complications...
3.
de Jong W, Geertsma R, Borchard G
Drug Deliv Transl Res . 2022 Jul; 12(9):2042-2047. PMID: 35908133
Nanotechnologies enable great opportunities for the development and use of innovative (nano)medicines. As is common for scientific and technical developments, recognized safety evaluation methods for regulatory purposes are lagging behind....
4.
de Jong W, Jennen D, Keizers P, Hodemaekers H, Vermeulen J, Bakker F, et al.
Int J Mol Sci . 2022 Jul; 23(13). PMID: 35806280
Resorbable tissue fillers for aesthetic purposes can induce severe complications including product migration, late swelling, and inflammatory reactions. The relation between product characteristics and adverse effects is not well understood....
5.
Zabeo A, Rosada F, Pizzol L, Caputo F, Borgos S, Parot J, et al.
Drug Deliv Transl Res . 2022 May; 12(9):2101-2113. PMID: 35538190
The application of nanomaterials in medicine has led to novel pharmaceuticals and medical devices that have demonstrated a strong potential for increasing the efficacy/performance and safety of therapeutic and diagnostic...
6.
Giannakou C, Park M, Bosselaers I, de Jong W, van der Laan J, Van Loveren H, et al.
Wiley Interdiscip Rev Nanomed Nanobiotechnol . 2020 Apr; 12(5):e1633. PMID: 32266791
Various nanomedicinal products (NMPs) have been reported to induce an adverse immune response, which may be related to their tendency to accumulate in or target cells of the immune system....
7.
van Baal J, Roszek B, van Elk M, Geertsma R
Expert Rev Med Devices . 2019 Oct; 16(10):899-911. PMID: 31564181
: Patients with severe aortic stenosis and regurgitation who are inoperable or at high-risk for surgery can be treated with transcatheter aortic valve replacement (TAVR). The aim of this study...
8.
Giannakou C, Aimonen K, van Bloois L, Catalan J, Geertsma R, Gremmer E, et al.
Nanomedicine (Lond) . 2019 May; 14(10):1231-1246. PMID: 31124759
Nanomaterials and nanomedicinal products tend to interfere with various commonly used assays, including regulatory required endotoxin detection methods for medicines. We developed a method to quantify endotoxin levels that is...
9.
Brand W, Noorlander C, Giannakou C, de Jong W, Kooi M, Park M, et al.
Int J Nanomedicine . 2017 Sep; 12:6107-6129. PMID: 28883724
Due to their specific properties and pharmacokinetics, nanomedicinal products (NMPs) may present different toxicity and side effects compared to non-nanoformulated, conventional medicines. To facilitate the safety assessment of NMPs, we...
10.
de Jong W, Burger M, Verheijen M, Geertsma R
Materials (Basel) . 2017 Sep; 3(9):4681-4694. PMID: 28883347
Gold nanoparticles of 10 nm and 250 nm were intravenously injected in rats. At 24 h after administration, tissues were collected and prepared for transmission electron microscopy (TEM). In the...